Cabaletta Bio
CABA
40 hedge funds and large institutions have $227M invested in Cabaletta Bio in 2019 Q4 according to their latest regulatory filings, with 40 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
67.69% more ownership
Funds ownership: 0% → 67.69% (+68%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$44.3M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$25.1M |
| 3 |
DM
Deerfield Management
New York
|
+$19.3M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$18.6M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$17M |
Top Sellers
CABA Hedge Fund Activity: Q4 2019 in Review
40 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Cabaletta Bio (CABA) for Q4 2019, worth a combined $227M.
Buyers outnumbered sellers: 40 funds opened new CABA positions and 0 closed out — a net gain of 40 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $44.3M.
- 40 institutional investors held Cabaletta Bio (CABA) as of Q4 2019, up from 0 in Q3 2019.
- Funds reported $227M of Cabaletta Bio stock for Q4 2019.
- 40 funds opened new Cabaletta Bio positions in Q4 2019 and 0 closed out, a net change of +40 holders.
- The largest Cabaletta Bio buyer in Q4 2019 was Adage Capital Partners, an estimated $44.3M added.
Based on aggregated 13F filings for Q4 2019.